Sign up
Pharma Capital

'We're not a one-trick pony', says N4 Pharma's Nigel Theobald

Nigel Theobald, chief executive and founder of N4 Pharma (LON:N4P) outlines the company's focus and strategy.

''We're not a one-trick pony'', says Theobald.

''What we have is a range of different drugs that we can bring to market but because we're reformulating we use all the safety and toxicity data from the existing drug''.

 

View full N4P profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.